Making Pharmaceutical Markets More Competitive Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Making Pharmaceutical Markets More Competitive Act
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of generic drug applications and supplements with respect to drugs that are in a shortage or for which there are not more than three approved drugs.
The holder of an approved drug application must notify the FDA within 180 days of withdrawing or transferring the application or withdrawing the drug from sale.
The FDA must maintain a list of generic drugs with three or fewer holders of approved applications.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 1115: Making Pharmaceutical Markets More Competitive Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-1115/
"S. 1115: Making Pharmaceutical Markets More Competitive Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-1115/.
S. 1115, 115th Cong. (2026), https://openamerica.io/bill/115-S-1115/.
[S. 1115: Making Pharmaceutical Markets More Competitive Act](https://openamerica.io/bill/115-S-1115/)